Figure 1. Structures and numbering for compounds

INTRODUCTION
As part of our ongoing research program on heterocyclic compounds which may serve as leads for designing novel chemotherapeutic agents, we have been involved on the preparation of pyrazolopyrimidines [1, 2] . These compounds and other related fused heterocycles are known to exhibit biological activity of several types such as CNS depressant [3] , neuroleptic [4] , tuberculostatic [5] , antibacterial and antifungal [2, 6] . It was also reported that pyrazolo[3,4-d]pyrimidines inhibit xanthine oxidase [7, 1] . 
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